James E. Siegler

Dr. James E. Siegler

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
JSJames E. Siegler
James E. Siegler
MHM.E. Heslin
M.E. Heslin
LTL. Thau
L. Thau
ASA. Smith
A. Smith
TJT.G. Jovin
T.G. Jovin

28 June 2021 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
NMNarges Moghimi
Narges Moghimi
MNMario Di Napoli
Mario Di Napoli
JBJosé Biller
José Biller
JSJames E. Siegler
James E. Siegler
Rahul ShekharRahul Shekhar
Rahul Shekhar
ADAfshin A. Divani
Afshin A. Divani

11 May 2011 in International Journal of Stroke
Verified
Journal Article
Closed access
JSJames E. Siegler
James E. Siegler
SMSheryl Martin-Schild
Sheryl Martin-Schild

1 March 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
SYShadi Yaghi
Shadi Yaghi
LSLiqi Shu
Liqi Shu
EBEkaterina Bakradze
Ekaterina Bakradze
SOSetareh Salehi Omran
Setareh Salehi Omran
JGJames Anthony Giles
James Anthony Giles
KFKaren Furie
Karen Furie
Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort. Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups. Results: Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140–720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51–1.73]; P =0.84), death (aHR, 0.78 [95% CI, 0.22–2.76]; P =0.70), and rate of partial/complete recanalization (aOR, 0.92 [95% CI, 0.48–1.73]; P =0.79), but a lower risk of major hemorrhage (aHR, 0.35 [95% CI, 0.15–0.82]; P =0.02). Conclusions: In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.

29 March 2021 in International Journal of Stroke
Verified
Journal Article
Open access
PDF file
RNRaul G. Nogueira
Raul G. Nogueira
MAMohamad Abdalkader
Mohamad Abdalkader
MQMuhammed M. Qureshi
Muhammed M. Qureshi
MFMichael R. Frankel
Michael R. Frankel
OMOssama Yassin Mansour
Ossama Yassin Mansour
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
Background: The COVID-19 pandemic led to profound changes in the organization of health care systems worldwide. Aims: We sought to measure the global impact of the COVID-19 pandemic on the volumes for mechanical thrombectomy, stroke, and intracranial hemorrhage hospitalizations over a three-month period at the height of the pandemic (1 March–31 May 2020) compared with two control three-month periods (immediately preceding and one year prior). Methods: Retrospective, observational, international study, across 6 continents, 40 countries, and 187 comprehensive stroke centers. The diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases at participating centers. Results: The hospitalization volumes for any stroke, intracranial hemorrhage, and mechanical thrombectomy were 26,699, 4002, and 5191 in the three months immediately before versus 21,576, 3540, and 4533 during the first three pandemic months, representing declines of 19.2% (95%CI, −19.7 to −18.7), 11.5% (95%CI, −12.6 to −10.6), and 12.7% (95%CI, −13.6 to −11.8), respectively. The decreases were noted across centers with high, mid, and low COVID-19 hospitalization burden, and also across high, mid, and low volume stroke/mechanical thrombectomy centers. High-volume COVID-19 centers (−20.5%) had greater declines in mechanical thrombectomy volumes than mid- (−10.1%) and low-volume (−8.7%) centers (p < 0.0001). There was a 1.5% stroke rate across 54,366 COVID-19 hospitalizations. SARS-CoV-2 infection was noted in 3.9% (784/20,250) of all stroke admissions. Conclusion: The COVID-19 pandemic was associated with a global decline in the volume of overall stroke hospitalizations, mechanical thrombectomy procedures, and intracranial hemorrhage admission volumes. Despite geographic variations, these volume reductions were observed regardless of COVID-19 hospitalization burden and pre-pandemic stroke/mechanical thrombectomy volumes.

1 July 2013 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
JSJames E. Siegler
James E. Siegler
ABAmelia K. Boehme
Amelia K. Boehme
AKAndre D. Kumar
Andre D. Kumar
MGMichael A. Gillette
Michael A. Gillette
KAKaren C. Albright
Karen C. Albright
SMSheryl Martin-Schild
Sheryl Martin-Schild